Cabozanitinib Shows Anti-Tumor Activity Beyond Clear-Cell Renal Cell Carcinoma

A recent study inThe Lancet Oncology suggests that the benefits of one tyrosine kinase inhibitor may extend to other subtypes of RCC.

Source: CancerNetwork - April 4, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news